BioAge Labs (BIOA) said Wednesday it is teaming up with Novartis (NVS) to identify drug targets to treat diseases related to aging.
The multiyear research collaboration will use BioAge's human longevity data and platform and Novartis' expertise in physical exercise biology, BioAge said.
The company said under the deal, it will get up to $20 million in upfront payments and research funding and may receive up to $530 million in future long-term research, development and commercial milestones.
Each company has the right to advance novel targets discovered under the partnership and is eligible to get reciprocal success milestones and tiered royalties, BioAge said.
Shares of BioAge jumped nearly 14% and Novartis fell 0.4% in recent Wednesday trading.
Price: 4.70, Change: +0.60, Percent Change: +14.63
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。